Your browser doesn't support javascript.
Potent mouse monoclonal antibodies that block SARS-CoV-2 infection.
Guo, Youjia; Kawaguchi, Atsushi; Takeshita, Masaru; Sekiya, Takeshi; Hirohama, Mikako; Yamashita, Akio; Siomi, Haruhiko; Murano, Kensaku.
  • Guo Y; Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan.
  • Kawaguchi A; Department of Infection Biology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan; Transborder Medical Research Center, University of Tsukuba, Tsukuba, Japan; Microbiology Research Center for Sustainability, University of Tsukuba, Tsukuba, Japan.
  • Takeshita M; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Sekiya T; Department of Infection Biology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Hirohama M; Department of Infection Biology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Yamashita A; Department of Molecular Biology, Yokohama City University School of Medicine, Yokohama, Japan.
  • Siomi H; Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan. Electronic address: awa403@keio.jp.
  • Murano K; Department of Molecular Biology, Keio University School of Medicine, Tokyo, Japan. Electronic address: kmurano@keio.jp.
J Biol Chem ; 296: 100346, 2021.
Article in English | MEDLINE | ID: covidwho-1056842
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has developed into a global pandemic since its first outbreak in the winter of 2019. An extensive investigation of SARS-CoV-2 is critical for disease control. Various recombinant monoclonal antibodies of human origin that neutralize SARS-CoV-2 infection have been isolated from convalescent patients and will be applied as therapies and prophylaxis. However, the need for dedicated monoclonal antibodies suitable for molecular pathology research is not fully addressed. Here, we produced six mouse anti-SARS-CoV-2 spike monoclonal antibodies that not only exhibit robust performance in immunoassays including western blotting, ELISA, immunofluorescence, and immunoprecipitation, but also demonstrate neutralizing activity against SARS-CoV-2 infection to VeroE6/TMPRSS2 cells. Due to their mouse origin, our monoclonal antibodies are compatible with the experimental immunoassay setups commonly used in basic molecular biology research laboratories, providing a useful tool for future research. Furthermore, in the hope of applying the antibodies of clinical setting, we determined the variable regions of the antibodies and used them to produce recombinant human/mouse chimeric antibodies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal / Antibodies, Viral Type of study: Prognostic study Topics: Vaccines Language: English Journal: J Biol Chem Year: 2021 Document Type: Article Affiliation country: J.jbc.2021.100346

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal / Antibodies, Viral Type of study: Prognostic study Topics: Vaccines Language: English Journal: J Biol Chem Year: 2021 Document Type: Article Affiliation country: J.jbc.2021.100346